Copanlisib is an intravenous PI3Ki that targets p110α and p110δ isoforms and is FDA-approved for relapsed follicular lymphoma [51] (Commissioner O. DA Approves New Treatment for Adults with Relapsed Follicular Lymphoma. Here, PIK3CD is linked to follicular lymphoma.